Jefferies Downgrades Amphastar Pharmaceuticals (AMPH) Due to Lack of Upside Catalysts
Jefferies downgraded Amphastar Pharmaceuticals (NASDAQ:AMPH) from Buy to Hold, citing a lack of meaningful upside catalysts and less impactful new product launches. The firm also lowered its price target for the stock to $22 from $30.
Tickers: $AMPH
Topics: Analyst Opinion Investment Strategy Pharmaceuticals Stock Downgrade